^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-1702

    i
    Other names: SHR-1702
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=8, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=84 --> 8 | Unknown status --> Terminated; Sponsor R & D Strategy Adjustment
    Enrollment change • Trial termination • Metastases
    |
    AiRuiKa (camrelizumab) • SHR-1702